Israeli medical imaging vendor Elscint has received 510(k) clearance for its version of a multislice CT scanner developed in partnership with Siemens Medical Systems of Iselin, NJ. The scanner is called Volumax CT Imaging System in Elscint’s 510(k)
Israeli medical imaging vendor Elscint has received 510(k) clearance for its version of a multislice CT scanner developed in partnership with Siemens Medical Systems of Iselin, NJ. The scanner is called Volumax CT Imaging System in Elscints 510(k) application, which was cleared on Sept. 2.
Volumax is based on the same technology used in Siemens Somatom Plus 4 Volume Zoom scanner, with some differences in components, according to an Elscint spokesperson. The system will probably be ready to ship in January.
Elscint and Siemens signed a CT technology development partnership in 1996 that culminated in the development of the Volume Zoom and Volumax scanners (SCAN 10/14/98). Each company has rights to sell its version of the technology under the terms of the deal. Picker Internationals pending acquisition of Elscints CT division will probably give the Cleveland vendor rights to sell Volumax, according to the Elscint spokesperson.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.